ClinicalTrials.gg
CompletedNCT02500277COFFEEUpdated Aug 31, 2018

Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy

An interventional study of Cryoprobe pleural biopsy first and Flexible forceps biopsy first in Pleural Effusion, Pleurisy and Tuberculosis, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Completed at 1 site in India. Open to participants aged 12 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
12 Years to 79 Years
Sex
All
01

Study summary

This is a prospective study to assess the yield of pleural biopsy obtained with the routine flexible thoracoscopic biopsy forceps versus that obtained with a flexible cryoprobe during semirigid thoracoscopy

Read the detailed description

Consecutive patients with exudative pleural effusions who are planned to undergo semirigid thoracoscopy will be enrolled in the study if they satisfy the inclusion criteria. They will be randomized in 1:1 ratio using a computer-generated randomization sequence to the following groups:

Group A: Four pleural biopsy specimens obtained using the flexible cryoprobe followed by eight pleural biopsy specimens obtained using the flexible thoracoscopic forceps OR Group B: The above two procedures will be performed in the reverse order The biopsies will be performed from different areas of the involved pleura with the two techniques. Thoracoscopy will be performed in the bronchoscopy suite on spontaneously breathing subjects (fasting for 8 h) under conscious sedation (using midazolam, pentazocine, and tramadol) observing complete aseptic precautions.

02

Conditions studied

  • Pleural Effusion
  • Pleurisy
  • Tuberculosis
  • Metastatic Malignancy

Keywords

  • thoracoscopy
  • pleuroscopy
  • semirigid thoracoscopy
  • flexible cryoprobe
  • cryobiopsy
  • pleural biopsy
03

In context

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.

This study's enrollment of 50 is below the median of 80 across 142 interventional studies indexed under Pleural Effusion.

Browse Pleural Effusion studies →

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥12 years
  • Semirigid thoracoscopy being performed for diagnosis of the pleural effusion

Exclusion criteria

Exclusion Criteria:

  • Age ≥80 years
  • SpO2 \<88% on room air
  • Hemodynamic instability
  • Myocardial infarction or unstable angina in the last 6 wk
  • Lack of pleural space due to adhesions
  • Uncorrected coagulopathy
  • Failure to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Cryobiopsy

    Pleural biopsy with a flexible cryoprobe

    Device: Cryoprobe pleural biopsy first

  • Active comparator
    Forceps biopsy

    Pleural biopsy with a flexible forceps

    Device: Flexible forceps biopsy first

Interventions

  • DeviceCryoprobe pleural biopsy first

    Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).

  • DeviceFlexible forceps biopsy first

    Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)

06

What researchers measure

Primary outcomes

  1. Yield of pleural biopsy obtained with the routine flexible thoracoscopic biopsy forceps versus that obtained with a flexible cryoprobe during semirigid thoracoscopy

    The proportion of patients where a definitive histopathological diagnosis was obtained will be compared between the cryoprobe and flexible forceps biopsy

    Time frame: One week

Secondary outcomes

  1. Biopsy size

    Size of biopsy specimens obtained with the two techniques

    Time frame: One day

  2. Duration of procedure

    Time taken for the procedure with the two techniques

    Time frame: One day

  3. Ease of biopsy VAS

    Ease of taking biopsy with the two techniques assessed using a visual analog scale

    Time frame: One day

  4. Artifacts

    Number of patient speciemens with histopathologic artifacts with either technique including crush artefacts with the flexible forceps and freeze artifacts with the cryoprobe

    Time frame: One day

  5. Tissue depth

    Depth of the tissue obtained on histopathology

    Time frame: One day

  6. Bleeding

    Number of participants with bleeding seen while taking biopsy categorised into "no bleeding", "minimal self limited ooze", "bleeding requiring prolonged suctioning" , "major hemorrhage requiring blood transfusion, causing hemodynamic instability or ICU admission"

    Time frame: One day

07

Study locations

1 site
  • PGIMER
    Chandigarh, 160012, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jul 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Jul 16, 2015
Start
Jan 2015
Primary completionActual
Jul 2018
CompletionActual
Jul 2018
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02500277
Responsible party
Sahajal Dhooria (Assistant Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Jul 16, 2015
Start date
Jan 2015
Primary completion
Jul 2018
Completion
Jul 2018
Last update
Aug 31, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion